Local and systhemic immunotherapy for bladder cancer: from bench to bedside

被引:0
|
作者
Carballido, Joaquin A. [1 ]
Vazquez Alba, David [1 ]
Rodriguez Monsalve, Maria [1 ]
机构
[1] Univ Autonoma Madrid, Fac Med, Serv & Catedra Urol, Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源
ARCHIVOS ESPANOLES DE UROLOGIA | 2020年 / 73卷 / 10期
关键词
Transitional cell bladder carcinom; Immunology and bladder cancer; Immunotherapy; Bacillus Calmette-Guerin; BCG Mechanism of action; BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL-CARCINOMA; BIOLOGICAL RESPONSE MODIFIERS; BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER ACTIVITY; T1 PAPILLARY CARCINOMA; TUMOR-NECROSIS-FACTOR; HIGH-RISK TA; INTRAVESICAL BCG; UROTHELIAL CARCINOMA;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic approaches for treatment of urothelial transitional cell carcinoma based on immune system modulation, as well as the contribution of introvesical Bacillus de Calmette-Guerin (BCG) and the recent incorporation of checkpoint inhibitors had found irrefutable proofs of concept for the indication of antitumoral immunontherapy in such tumors. Its extension and development at the present time covers all the locations of the wide spectrum of presentation and evolution of these tumors. Nowadays, apart for the low grade non muscle-invasive tumors, we are facing an unpredictable development of antitumoral immunotherapy in bladder cancer not only as an option in the primary treatment, but also in other scenarios such as non-responders when it comes to BCG, or the situation of ineligibility for systemic chemotherapy indication. The main objective of this review article is trying to translate the current basic mechanisms involved in different phases of transitional cell carcinomas antitumoral response, regardless of whether they are muscle-invasive or not, and to establish the rationale for their therapeutic intravesical or systemic administration. The role of the interactions established between urothelial tumor cells and the cellular and molecular elements of the immune system of patients is described, incorporating the relevant and recent advances in immunobiology and the molecular characterization of these tumors that will undoubtedly introduce far-reaching modifications in therapeutic regimes that will contrast with the traditional options available. Investigational lines that are already active in the clinical research phase with BCG and, checkpoints inhibitors of the immune response are also analyzed, highlighting the need to find predictive response markers as a real option for treatments personalization. The approach to the knowledge of the individual reactivity of the immune system of each patient as a determining factor to achieve it is proposed.
引用
收藏
页码:879 / 894
页数:16
相关论文
共 50 条
  • [41] Normalizing the Tumor Microenvironment to Improve Cancer Immunotherapy: Bench to Bedside and Back
    Jain, Rakesh K.
    CANCER SCIENCE, 2023, 114 : 1591 - 1591
  • [42] Engineering artificial antigen presenting cells, aAPC, for cancer immunotherapy: From bench to bedside.
    Schneck, Jonathan P.
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (02)
  • [43] Translating sperm protein 17 as a target for immunotherapy from the bench to the bedside in the light of cancer complexity
    Grizzi, F.
    Chiriva-Internati, M.
    TISSUE ANTIGENS, 2013, 81 (02): : 116 - 118
  • [44] Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside
    Kanani, Arezo
    Veen, Torhild
    Alexeeva, Marina
    Lea, Dordi
    Soreide, Kjetil
    MINERVA SURGERY, 2023, 78 (04): : 385 - 400
  • [45] Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside
    Morera-Diaz, Yanelys
    Gavilondo, Jorge V.
    Bequet-Romero, Monica
    Sanchez Ramirez, Javier
    Hernandez-Bernal, Francisco
    Selman-Housein, Katty-Hind
    Perez, Lincidio
    Ayala-Avila, Marta
    SEMINARS IN ONCOLOGY, 2018, 45 (1-2) : 68 - 74
  • [46] Urticaria: "From bench to bedside" [Urtikaria: "From bench to bedside"]
    Magerl M.
    Maurer M.
    Der Hautarzt, 2007, 58 (4): : 308 - 313
  • [47] Moving cancer diagnostics from bench to bedside
    Zhang, Xuewu
    Li, Lin
    Wei, Dong
    Chen, Feng
    TRENDS IN BIOTECHNOLOGY, 2007, 25 (04) : 166 - 173
  • [48] Peritoneal dialysis: from bench to bedside and bedside to bench
    Perl, Jeffrey
    Bargman, Joanne M.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 311 (05) : F999 - F1004
  • [49] Cancer stem cells: From bench to bedside
    Jones, Richard J.
    Matsui, William
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) : 47 - 52
  • [50] Breast cancer research from bench to bedside
    Minoru Fujimori
    Breast Cancer, 2010, 17 : 79 - 79